
Evommune Inc (EVMN) Stock Forecast & Price Target
Evommune Inc (EVMN) Analyst Ratings
Bulls say
Evommune is in a unique position to address the needs of patients with chronic inflammatory diseases through its differentiated pipeline targeting key drivers of disease. EVO756, the company's MRGPRX2 antagonist, has shown promise in clinical trials for chronic inducible urticaria (CIndU) and could potentially have a significant market opportunity in chronic spontaneous urticaria (CSU). EVO301, an IL-18 fusion protein inhibitor, also has potential in AD and UC. The company's strong pipeline, coupled with positive clinical data and potential for expansion into additional indications, make it an attractive investment opportunity.
Bears say
Evommune is currently in its early stages of clinical development, with its lead asset EVO756 targeting chronic spontaneous urticaria (CSU) and atopic dermatitis (AD). While the company may have promising early signals for EVO756 and IL-18 '301, the potential for '756 in other indications such as migraine appears overlooked with concerns around safety, expenses, and non-revenue-generating status. Estimated 2035E global sales of $1.7B for EVO756/CSU and $1.5B for EVO301/AD could potentially support a valuation of $42 per share, but there remain unmet needs in the market and potential risks with other approved therapies.
This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.
Evommune Inc (EVMN) Analyst Forecast & Price Prediction
Start investing in Evommune Inc (EVMN)
Order type
Buy in
Order amount
Est. shares
0 shares